Piragliatin (BioDeep_00000413096)
代谢物信息卡片
化学式: C19H20ClN3O4S (421.0862990000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CS(=O)(=O)C1=C(C=C(C=C1)C(CC2CCC(=O)C2)C(=O)NC3=NC=CN=C3)Cl
InChI: InChI=1S/C19H20ClN3O4S/c1-28(26,27)17-5-3-13(10-16(17)20)15(9-12-2-4-14(24)8-12)19(25)23-18-11-21-6-7-22-18/h3,5-7,10-12,15H,2,4,8-9H2,1H3,(H,22,23,25)/t12-,15+/m0/s1
描述信息
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3431; ORIGINAL_PRECURSOR_SCAN_NO 3429
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3421; ORIGINAL_PRECURSOR_SCAN_NO 3418
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3414; ORIGINAL_PRECURSOR_SCAN_NO 3413
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3421; ORIGINAL_PRECURSOR_SCAN_NO 3419
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3430; ORIGINAL_PRECURSOR_SCAN_NO 3428
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7552; ORIGINAL_PRECURSOR_SCAN_NO 7548
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7558; ORIGINAL_PRECURSOR_SCAN_NO 7553
INTERNAL_ID 985; CONFIDENCE standard compound; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7580; ORIGINAL_PRECURSOR_SCAN_NO 7576
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7580; ORIGINAL_PRECURSOR_SCAN_NO 7576
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7590; ORIGINAL_PRECURSOR_SCAN_NO 7586
同义名列表
1 个代谢物同义名
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hiroki Fujieda, Masakazu Kogami, Masao Sakairi, Noriyasu Kato, Mitsuhiro Makino, Naoki Takahashi, Toshiyuki Miyazawa, Satoko Harada, Tokuyuki Yamashita. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
European journal of medicinal chemistry.
2018 Aug; 156(?):269-294. doi:
10.1016/j.ejmech.2018.06.060. [PMID: 30006171] - S Zhai, A Georgy, Z Liang, J Zhi. Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
Clinical pharmacology in drug development.
2016 Nov; 5(6):552-556. doi:
10.1002/cpdd.276. [PMID: 27274007] - Jianguo Zhi, Suoping Zhai, Angela Georgy, Zhenming Liang, Mark Boldrin. Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Journal of clinical pharmacology.
2016 May; 56(5):548-54. doi:
10.1002/jcph.617. [PMID: 26272330] - Jianguo Zhi, Suoping Zhai. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
Journal of clinical pharmacology.
2016 Feb; 56(2):231-8. doi:
10.1002/jcph.589. [PMID: 26183686] - Nirav Dhanesha, Amit Joharapurkar, Gaurang Shah, Samadhan Kshirsagar, Vishal Patel, Kartik Patel, Rajesh Bahekar, Mukul Jain. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
European journal of pharmacology.
2013 Aug; 714(1-3):188-92. doi:
10.1016/j.ejphar.2013.06.015. [PMID: 23810686] - Riccardo C Bonadonna, Tim Heise, Christophe Arbet-Engels, Christoph Kapitza, Angelo Avogaro, Joe Grimsby, Jay Zhi, Joseph F Grippo, Raffaella Balena. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.
The Journal of clinical endocrinology and metabolism.
2010 Nov; 95(11):5028-36. doi:
10.1210/jc.2010-1041. [PMID: 20739378]